Wanted: Large-scale vaccine manufacturer for coronavirus vaccine
Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Follow the latest updates of the outbreak on our timeline. Moderna’s…
Read More…
Focus:
Global
-
![]()
China coronavirus outbreak is advancing fast and furiously; what to expect next?
The five key events we at GlobalData had identified to watch for during the novel coronavirus outbreak occurred in the…
Read More…
-
![]()
Different therapeutic regimens continue to show promise in multiple myeloma
A number of therapeutic approaches are being evaluated for the treatment of multiple myeloma with very promising assets in the…
Read More…
-
![]()
Major boost to heart failure market expected
GlobalData expects that the heart failure market will see large growth over 2018–2028, with a Compound Annual Growth Rate (CAGR)…
Read More…
-
![]()
AstraZeneca acquires global rights to brazikumab following AbbVie’s pending acquisition of Allergan
On January 27 2020, AstraZeneca announced that the global rights for brazikumab, an interleukin 23 (IL-23) inhibitor that is currently…
Read More…
-
![]()
Divergent pricing and reimbursement conditions: a hurdle for marketing orphan drugs
Variation in pricing and reimbursement considerations across different geographies requires standardisation to enable companies and patients to benefit more broadly…
Read More…
-
![]()
Coronavirus: Death toll reaches 132 in China; Confirmed cases pass 6000
The death toll from the new coronavirus outbreak has reached 132 in China, as of...
Read More...
-
![]()
Potential treatment approaches race to fight coronavirus outbreak
Follow the latest updates of the outbreak on our timeline. The new coronavirus outbreak continues to accelerate its spread, with more than…
Read More…
-
![]()
Lower prevalence of obesity in Japan due to environmental factors
The global prevalence of obesity continues to rise, with over 2,000,000,000 people worldwide described as overweight or obese by the…
Read More…
-
![]()
Eli Lilly bolsters its dermatology portfolio with Dermira acquisition
On January 10, Eli Lilly announced that it had acquired Dermira for $1.1B in a bid to bolster its dermatology…
Read More…
